The Biostatistics &Bioinformatics Core will support investigators of the SPORE in Soft Tissue Sarcoma in the computational and statistical aspects of their research efforts, including the design and analysis of clinical trials, laboratory experiments, molecular profiling, and sequencing, as well as integrated genomic analyses. In the clinical trial design phase, a core member will conduct a protocol review with the principal investigator. Based on this review, a statistical section for the protocol will be provided, outlining major scientific objectives, population to be studied, primary and secondary endpoints, experimental design, analysis plans, and a targeted sample size justified in probabilistic terms. At the conclusion of the trial, data analyses will be performed to assess outcomes of the primary and secondary endpoints stated in the protocol. In preclinical studies, core members will assist in the formulation of the experimental design and in the analysis and interpretation of the data at the conclusion of the study. The core will also assist in the large-scale molecular characterization of human sarcoma samples, which involves analyzing RNA expression, microRNA expression, mutations, and DNA copy number changes to identify predictors of tumor characteristics, drug response, and survival. Core members will use two-sample t-tests and Cox proportional hazards models to identify informative features. The different types of molecular data will be integrated and pathway analysis performed to elucidate the pathways that contribute to tumorigenesis and tumor phenotype. Risk prediction tools will be developed using Cox proportional hazards models based on these features.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA140146-04
Application #
8515349
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
4
Fiscal Year
2013
Total Cost
$89,061
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Katabi, Nora; Xu, Bin; Jungbluth, Achim A et al. (2018) PLAG1 immunohistochemistry is a sensitive marker for pleomorphic adenoma: a comparative study with PLAG1 genetic abnormalities. Histopathology 72:285-293
Argani, Pedram; Pawel, Bruce; Szabo, Sara et al. (2018) Diffuse Strong BCOR Immunoreactivity Is a Sensitive and Specific Marker for Clear Cell Sarcoma of the Kidney (CCSK) in Pediatric Renal Neoplasia. Am J Surg Pathol 42:1128-1131
Xie, Yuanyuan; Cao, Zhen; Wong, Elissa Wp et al. (2018) COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors. J Clin Invest 128:1442-1457
Moore, Amanda R; Ran, Leili; Guan, Youxin et al. (2018) GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma. Cell Rep 22:2455-2468
Dickson, Brendan C; Antonescu, Cristina R; Argyris, Prokopios P et al. (2018) Ectomesenchymal Chondromyxoid Tumor: A Neoplasm Characterized by Recurrent RREB1-MKL2 Fusions. Am J Surg Pathol 42:1297-1305
Weinreb, Ilan; Bishop, Justin A; Chiosea, Simion I et al. (2018) Recurrent RET Gene Rearrangements in Intraductal Carcinomas of Salivary Gland. Am J Surg Pathol 42:442-452
Kao, Yu-Chien; Flucke, Uta; Eijkelenboom, Astrid et al. (2018) Novel EWSR1-SMAD3 Gene Fusions in a Group of Acral Fibroblastic Spindle Cell Neoplasms. Am J Surg Pathol 42:522-528
Bartenstein, Diana W; Coe, Taylor M; Gordon, Samantha C et al. (2018) Lipofibromatosis-like neural tumor: Case report of a unique infantile presentation. JAAD Case Rep 4:185-188
Chen, Yu; Chi, Ping (2018) Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers. J Hematol Oncol 11:78
Owosho, Adepitan A; Estilo, Cherry L; Huryn, Joseph M et al. (2018) A Clinicopathologic Study of Head and Neck Malignant Peripheral Nerve Sheath Tumors. Head Neck Pathol 12:151-159

Showing the most recent 10 out of 169 publications